STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lung cancer drug combo tested in Mid-Stage trial
Disease control OngoingThis phase 2 trial tests two drugs, erlotinib and cabozantinib, given alone or together in 125 patients with advanced non-small cell lung cancer that does not have a common EGFR mutation. The goal is to see if the combination works better than either drug alone to slow cancer gro…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two targeted drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The main goals are to find the safest dose and understand side effects.…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-phase trial tests the combination of two oral drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC) that has stopped responding to standard treatments. The main goal is to find a safe dose and look …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Heat and radiation team up to fight spine cancer
Disease control OngoingThis study tests whether combining two treatments—thermal ablation (using heat to destroy tumor cells) and stereotactic radiosurgery (precise, high-dose radiation)—can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with vari…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can adding radiation boost immunotherapy against tough cancers?
Disease control OngoingThis phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with or without radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 participants will receive the drugs alone or with hig…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC